We are comparing Acorda Therapeutics Inc. (NASDAQ:ACOR) and Matinas BioPharma Holdings Inc. (NYSEAMERICAN:MTNB) on their profitability, analyst recommendations, risk, dividends, institutional ownership, earnings and valuation. They both are Biotechnology companies, competing one another.

Earnings & Valuation

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acorda Therapeutics Inc.	471.43M	1.34	33.68M	0.71	20.63
Matinas BioPharma Holdings Inc.	N/A	1017.82	14.87M	-0.16	0.00

Table 1 shows the gross revenue, earnings per share (EPS) and valuation for Acorda Therapeutics Inc. and Matinas BioPharma Holdings Inc.

Profitability

Table 2 demonstrates the return on assets, net margins and return on equity of Acorda Therapeutics Inc. and Matinas BioPharma Holdings Inc.

	Net Margins	Return on Equity	Return on Assets
Acorda Therapeutics Inc.	7.14%	5.7%	2.7%
Matinas BioPharma Holdings Inc.	0.00%	0%	-104.5%

Risk & Volatility

Acorda Therapeutics Inc. has a 1.47 beta, while its volatility is 47.00% which is more volatile than Standard & Poor’s 500. Competitively, Matinas BioPharma Holdings Inc.?s 130.00% volatility makes it more volatile than Standard & Poor’s 500, because of the 2.3 beta.

Liquidity

The current Quick Ratio of Acorda Therapeutics Inc. is 3.6 while its Current Ratio is 3.8. Meanwhile, Matinas BioPharma Holdings Inc. has a Current Ratio of 2.9 while its Quick Ratio is 2.9. Acorda Therapeutics Inc. is better positioned to pay off its short-term and long-term debts than Matinas BioPharma Holdings Inc.

Analyst Recommendations

Acorda Therapeutics Inc. and Matinas BioPharma Holdings Inc. Ratings and Recommendations are available on the next table.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
Acorda Therapeutics Inc.	1	2	1	2.25
Matinas BioPharma Holdings Inc.	0	0	0	0.00

The upside potential is 55.53% for Acorda Therapeutics Inc. with consensus target price of $20.67.

Insider and Institutional Ownership

Institutional investors held 0% of Acorda Therapeutics Inc. shares and 11.7% of Matinas BioPharma Holdings Inc. shares. Insiders held 1.4% of Acorda Therapeutics Inc. shares. Comparatively, 0.7% are Matinas BioPharma Holdings Inc.’s share held by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Acorda Therapeutics Inc.	9.02%	-12.03%	-29.7%	-48.85%	-39.92%	-6.1%
Matinas BioPharma Holdings Inc.	18.35%	17.27%	54.07%	200%	27.72%	116.81%

For the past year Acorda Therapeutics Inc. has -6.1% weaker performance while Matinas BioPharma Holdings Inc. has 116.81% stronger performance.

Summary

Acorda Therapeutics Inc. beats on 9 of the 11 factors Matinas BioPharma Holdings Inc.

Acorda Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); Zanaflex capsules and tablets for the management of spasticity; and Qutenza, a dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops CVT-301 that has completed a Phase III clinical trial for the treatment of OFF periods in Parkinson’s disease; CVT-427, which has completed a Phase I clinical trial to treat migraine; Tozadenant that is in Phase III clinical trial for reduction of OFF time in Parkinson’s disease; SYN120, which is in Phase II clinical trial to treat Parkinson’s disease-related dementia; and BTT1023 (timolumab) that is in Phase II clinical trial for primary sclerosing cholangitis. Further, it develops rHIgM22, which is in Phase I clinical trial for the treatment of MS; Cimaglermin alfa that has completed a Phase I clinical trial in heart failure patients; and Chondroitinase Program that is in research stage for the treatment of spinal cord injury. The company has collaborations and license agreements with Biogen International GmbH; Alkermes plc; Rush-Presbyterian St. Luke's Medical Center; Alkermes, Inc.; SK Biopharmaceuticals Co., Ltd.; Astellas Pharma Europe Ltd.; Canadian Spinal Research Organization; Cambridge Enterprise Limited and King's College London; Mayo Foundation for Education and Research; Paion AG; Medarex, Inc.; and Brigham and Women’s Hospital, Inc. Acorda Therapeutics, Inc. was founded in 1995 and is headquartered in Ardsley, New York.

Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing therapeutics for the treatment of fungal and bacterial infections. The company develops orally delivered therapeutics based on a proprietary, lipid-based drug delivery platform called cochleate delivery technology. Its lead product candidate is MAT 2203, an orally-administered cochleate formulation of the broad spectrum anti-fungal drug amphotericin B that is in Phase II study for the treatment of fungal infections. The company is also involved in developing MAT2501, an orally-administered, encochleated formulation of aminoglycoside antibiotic agent amikacin for acute bacterial infections, including non-tuberculous mycobacterium (NTM) and multi-drug resistant gram negative bacterial infections. In addition, it is exploring strategic partnership options for MAT8800 discovery program, which intends to identify product candidates derived from omega-3 fatty acids for the treatment of non-alcoholic fatty liver disease. Matinas BioPharma Holdings, Inc. was incorporated in 2013 and is based in Bedminster, New Jersey.